Navigation Links
CPF, Pulmonary Fibrosis Experts Guests on Sirius and XM Satellite Radio Show June 16th
Date:6/15/2009

"Doctor Radio" Host Interviews CPF Co-Founder, PF Advocate, and Top PF Researcher and Clinician

NEW YORK, June 15 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced its co-founder and other Pulmonary Fibrosis (PF) experts will be guests on the Sirius and XM Satellite Radio Show "Doctor Radio" on Tuesday, June 16th from 6-7 a.m. EDT. For non-Sirius and XM radio subscribers, the show can be heard via a free pass available on the Internet.

Sirius and XM Satellite Radio Interview with CPF, PF Experts

Show: Doctor Radio

Host: Frank Adams, MD

Subject: Pulmonary Fibrosis

Guests: Coalition for Pulmonary Fibrosis Chief Operating Officer and Co-Founder Mark Shreve; Family member of PF patient, legislative advocate and CPF fundraiser Terence Hales; and pulmonologist and world renowned PF researcher and clinician, Maria Padilla, MD, of Mount Sinai Medical Center in New York City.

Date: Tuesday, June 16th, 2009

Time: 6-7 a.m., EDT

Listen online: To listen to the interview online, sign up with an email address for a free pass at http://www.sirius.com/freetrial/register.

Listeners can hear the show live on Tuesday, June 16th or can listen to the repeat which airs from 4-6 p.m. EDT on Tuesday, June 16th. Sirius and XM Satellite Radio subscribers can also listen in on satellite radio.

About Pulmonary Fibrosis (PF)

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 19,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
2. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
3. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
4. Resolution Recognizing Pulmonary Fibrosis Challenges Overwhelmingly Passes House
5. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
6. Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF
7. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
8. A new method allows for the early diagnosis of pulmonary hypertension
9. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
10. Free Program Dec. 1 to Help Patients With Debilitating Pulmonary Disorder Alpha-1
11. Evel Knievel Lost to Pulmonary Fibrosis; Disease Claims as Many Lives as Breast Cancer Each Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology: